• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by SCYNEXIS Inc.

    6/9/23 4:29:52 PM ET
    $SCYX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SCYX alert in real time by email
    SC 13G 1 scynexis13g.htm

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934
    (Amendment No. ___)*

     

     

    Scynexis, Inc.

    (Name of Issuer)

     

     

    Common Stock, par value $0.001per share

    (Title of Class of Securities)

     

     

    811292200

    (CUSIP Number)

     

     

    May 31, 2023

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    [X]       Rule 13d-1(b)

     

    [X]       Rule 13d-1(c)

     

    [ ]       Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

     

     1 
    CUSIP No. 811292200

     

    1.Names of Reporting Persons.

    Stonepine Capital Management, LLC

     

    2.Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) ______

    (b) X

     

    3. SEC Use Only

     

    4.Citizenship or Place of Organization California

     

    Number of

    Shares

    Beneficially

    Owned by

    Each Reporting

    Person With:

    5. Sole Voting Power 0

     

    6. Shared Voting Power 2,777,877

     

    7. Sole Dispositive Power 0
    8. Shared Dispositive Power 2,777,877

     

    9.Aggregate Amount Beneficially Owned by Each Reporting Person 2,777,877

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See
    Instructions) ______

     

    11.Percent of Class Represented by Amount in Row (9) 7.6%

     

    12.Type of Reporting Person (See Instructions) IA, OO

     

     2 
    CUSIP No. 811292200

     

    1.Names of Reporting Persons.

    Stonepine Capital, L.P.

     

    2.Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) ______

    (b) X

     

    3. SEC Use Only

     

    4.Citizenship or Place of Organization Delaware

     

    Number of

    Shares

    Beneficially

    Owned by

    Each Reporting

    Person With:

    5. Sole Voting Power 0

     

    6. Shared Voting Power 2,777,877

     

    7. Sole Dispositive Power 0
    8. Shared Dispositive Power 2,777,877

     

    9.Aggregate Amount Beneficially Owned by Each Reporting Person 2,777,877

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See
    Instructions) ______

     

    11.Percent of Class Represented by Amount in Row (9) 7.6%

     

    12.Type of Reporting Person (See Instructions) PN

     

     3 
    CUSIP No. 811292200

    Names of Reporting Persons.

    Jon M. Plexico

     

    2.Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) ______

    (b) X

     

    3. SEC Use Only

     

    4.Citizenship or Place of Organization U.S.A.

     

    Number of

    Shares

    Beneficially

    Owned by

    Each Reporting

    Person With:

    5. Sole Voting Power 0

     

    6. Shared Voting Power 2,777,877

     

    7. Sole Dispositive Power 0
    8. Shared Dispositive Power 2,777,877

     

    9.Aggregate Amount Beneficially Owned by Each Reporting Person 2,777,877

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See
    Instructions) ______

     

    11.Percent of Class Represented by Amount in Row (9) 7.6%

     

    12.Type of Reporting Person (See Instructions) HC, IN

     

     4 
    CUSIP No. 811292200

    Names of Reporting Persons.

    Timothy P. Lynch

     

    2.Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) ______

    (b) X

     

    3. SEC Use Only

     

    4.Citizenship or Place of Organization U.S.A.

     

    Number of

    Shares

    Beneficially

    Owned by

    Each Reporting

    Person With:

    5. Sole Voting Power 0

     

    6. Shared Voting Power 2,777,877

     

    7. Sole Dispositive Power 0
    8. Shared Dispositive Power 2,777,877

     

    9.Aggregate Amount Beneficially Owned by Each Reporting Person 2,777,877

     

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See
    Instructions) ______

     

    11.Percent of Class Represented by Amount in Row (9) 7.6%

     

    12.Type of Reporting Person (See Instructions) HC, IN

     

     5 
    CUSIP No. 811292200

    Item 1.

     

    (a)Name of Issuer

    Scynexis, Inc.

     

    (b)Address of Issuer’s Principal Executive Offices

    1 Evertrust Plaza, 13th Floor, Jersey City, NJ 07302-6548

     

     

    Item 2.

     

    (a)The names of the persons filing this statement are:


    Stonepine Capital Management, LLC, a California limited liability company (the “General Partner”)

     

    Stonepine Capital, L.P., a Delaware limited partnership (the “Partnership”)

     

    Jon M. Plexico

     

    Timothy P. Lynch (collectively, the “Filers”)

     

    The General Partner is the general partner and investment adviser of investment funds, including the Partnership. Mr. Plexico and Mr. Lynch are the control persons of the General Partner. The Filers are filing this Schedule 13G jointly, but not as members of a group, and each disclaims membership in a group. Each Filer also disclaims beneficial ownership of the Stock except to the extent of that person’s pecuniary interest therein. In addition, the filing of this Schedule 13G on behalf of the Partnership should not be construed as an admission that it is, and it disclaims that it is, a beneficial owner, as defined in Rule 13d-3 under the Act, of any of the Stock covered by this Schedule 13G.

     

    (b)The principal business office of the Filers is located at

     

    919 NW Bond Street, Suite 204

    Bend, OR 97703

     

    (c)For citizenship of Filers, see Item 4 of the cover sheet for each Filer.

     

    (d)This statement relates to the Issuer’s Common Stock, par value $0.001per share (the “Stock”).

     

    (e)The CUSIP number of the Issuer is: 811292200
     6 
    CUSIP No. 811292200
    Item 3.If this statement is filed pursuant to rule 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a)[ ] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

     

    (b)[ ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

     

    (c)[ ] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

     

    (d)[ ] Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

     

    (e)[X] An investment adviser in accordance with section 240.13d-1(b)(1)(ii)(E). As to the General Partner.

     

    (f)[ ] An employee benefit plan or endowment fund in accordance with section 240.13d-1(b)(1)(ii)(F).

     

    (g)[X] A parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G). As to Mr. Plexico and Mr. Lynch.

     

    (h)[ ] A savings association as defined in section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).

     

    (i)[ ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3).

     

    (j)[ ] A non-U.S. institution in accordance with §240.13d-1(b)(ii)(J).

     

    (k)[ ] Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

    If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution _______________________________________________________________.

     

    Item 4.Ownership.

     

    See Items 5-9 and 11 of the cover page for each Filer.

     

    The percentages reported in this Schedule 13G are based on 36,517,442 shares of Common Stock outstanding as of May 1, 2023, as reported in the Form 10-Q filed by the Issuer on May 10, 2023.

     

    Item 5.Ownership of Five Percent or Less of a Class

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ].

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    The Partnership holds the Stock for the benefit of its investors and has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Stock.

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

     

    Not applicable.

     

    Item 8.Identification and Classification of Members of the Group.

     

    Not applicable.

     

    Item 9.Notice of Dissolution of Group

     

    Not applicable.


    Item 10.
    Material to Be Filed as Exhibits

    Agreement Regarding Joint Filing of Statement on Schedule 13D or 13G.

    Item 11.Certification of the General Partner, Mr. Plexico and Mr. Lynch

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

    Certification of the Partnership

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     7 
    CUSIP No. 811292200

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: June 9, 2023

     

     

    STONEPINE CAPITAL MANAGEMENT, LLC


    By:
    .s. Timothy P. Lynch

    Timothy P. Lynch, Managing Member

     

     

    STONEPINE CAPITAL, L.P.

    By:
    Stonepine Capital Management, LLC,
    General Partner

    By: /s/ Timothy P. Lynch

    Timothy P. Lynch, Managing Member

     

     

     

    /s/ Jon M. Plexico

    Jon M. Plexico

     

     

    /s/ Timothy P. Lynch

    Timothy P. Lynch

     

     8 
    CUSIP No. 811292200

    EXHIBIT A

     

    AGREEMENT REGARDING JOINT FILING

    OF STATEMENT ON SCHEDULE 13D OR 13G

     

    The undersigned agree to file jointly with the Securities and Exchange Commission (the “SEC”) any and all statements on Schedule 13D or Schedule 13G or Forms 3, 4 or 5(and any amendments or supplements thereto) required under section 13(d) and 16(a) of the Securities Exchange Act of 1934, as amended, in connection with purchases by the undersigned of the securities of any issuer. For that purpose, the undersigned hereby constitute and appoint Stonepine Capital Management, LLC, a California limited liability company, as their true and lawful agent and attorney-in-fact, with full power and authority for and on behalf of the undersigned to prepare or cause to be prepared, sign, file with the SEC and furnish to any other person all certificates, instruments, agreements and documents necessary to comply with section 13(d) and section 16(a) of the Securities Exchange Act of 1934, as amended, in connection with said purchases, and to do and perform every act necessary and proper to be done incident to the exercise of the foregoing power, as fully as the undersigned might or could do if personally present.

     

    Dated: May 15, 2017

     

     

    STONEPINE CAPITAL MANAGEMENT, LLC


    By:
    /s/ Timothy P. Lynch
    Managing Member

     

      STONEPINE CAPITAL, L.P.

    By: Stonepine Capital Management, LLC,
    General Partner

    By: /s/ Timothy P. Lynch
    Managing Member
     
    /s/ Jon M. Plexico
      /s/ Timothy P. Lynch

     

    Get the next $SCYX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SCYX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SCYX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Aegis Capital reiterated coverage on SCYNEXIS with a new price target

      Aegis Capital reiterated coverage of SCYNEXIS with a rating of Buy and set a new price target of $35.00 from $40.00 previously

      6/7/21 9:58:05 AM ET
      $SCYX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aegis Capital reiterated coverage on SCYNEXIS with a new price target

      Aegis Capital reiterated coverage of SCYNEXIS with a rating of Buy and set a new price target of $40.00 from $45.00 previously

      4/12/21 12:54:40 PM ET
      $SCYX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Maxim Group reiterated coverage on SCYNEXIS with a new price target

      Maxim Group reiterated coverage of SCYNEXIS with a rating of Buy and set a new price target of $22.00 from $17.00 previously

      2/17/21 2:23:39 PM ET
      $SCYX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SCYX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Angulo Gonzalez David was granted 23,000 shares, increasing direct ownership by 3% to 816,598 units (SEC Form 4)

      4 - SCYNEXIS INC (0001178253) (Issuer)

      4/10/25 8:02:09 AM ET
      $SCYX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Angulo Gonzalez David was granted 18,800 shares, increasing direct ownership by 2% to 793,598 units (SEC Form 4)

      4 - SCYNEXIS INC (0001178253) (Issuer)

      3/20/25 7:39:22 PM ET
      $SCYX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Legal Officer Sukenick Scott was granted 92,511 shares, increasing direct ownership by 27% to 436,706 units (SEC Form 4)

      4 - SCYNEXIS INC (0001178253) (Issuer)

      1/27/25 4:05:22 PM ET
      $SCYX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SCYX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for BREXAFEMME issued to SCYNEXIS, INC

      Submission status for SCYNEXIS, INC's drug BREXAFEMME (ORIG-1) with active ingredient IBREXAFUNGERP has changed to 'Approval' on 06/01/2021. Application Category: NDA, Application Number: 214900, Application Classification: Type 1 - New Molecular Entity

      6/2/21 11:20:46 AM ET
      $SCYX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for BREXAFEMME issued to SCYNEXIS, INC

      Submission status for SCYNEXIS, INC's drug BREXAFEMME (SUPPL-1) with active ingredient IBREXAFUNGERP has changed to 'Approval' on 06/01/2021. Application Category: NDA, Application Number: 214900, Application Classification: Type 1 - New Molecular Entity

      6/2/21 9:57:42 AM ET
      $SCYX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SCYX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • SCYNEXIS Resumes Patient Dosing in Phase 3 MARIO Study

      First new patient dosed in Phase 3 MARIO study following the lifting of the FDA clinical holdResumption of dosing in this study triggers a $10M milestone payment from GSK plus an additional $20M milestone due in six months; as previously disclosed GSK disputes these milestone payments, and SCYNEXIS vigorously disagrees with their position JERSEY CITY, N.J., May 28, 2025 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that patient dosing has resumed in the Phase 3 MARIO study, which is an innovative study to investigate oral ibrexafungerp as a

      5/28/25 8:30:00 AM ET
      $SCYX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SCYNEXIS Reports First Quarter 2025 Financial Results and Provides Corporate Update

      Ibrexafungerp clinical hold lifted by the FDA. SCYNEXIS working to resolve a disagreement with GSK involving the restart of the MARIO study. GSK remains committed to the commercialization of Brexafemme.Hansoh recently received Chinese (NMPA) approval for ibrexafungerp in the treatment of acute VVC. SCYNEXIS will receive a milestone payment from Hansoh upon commercialization as well as royalties of approximately 10% on China sales.Presented positive preclinical data for its second-generation fungerp candidate, SCY-247, at the European Society of Clinical Microbiology and Infectious Disease (ESCMID) meeting; Company expects to report initial Phase 1 data for SCY-247 in Q3 2025.    SCYNEXIS end

      5/15/25 4:20:00 PM ET
      $SCYX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SCYNEXIS to Present Preclinical Data on Second Generation IV/Oral Fungerp SCY-247 at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID)

      JERSEY CITY, N.J., April 08, 2025 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the presentation of preclinical efficacy data on its second-generation fungerp candidate SCY-247 at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global) in Vienna, Austria being held from April 11-15, 2025. SCY-247 is being developed to address systemic fungal diseases, with a key focus on invasive fungal infections where resistance to current limited treatment options is a significant concern. These presentations at ESCMID Global

      4/8/25 8:00:00 AM ET
      $SCYX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SCYX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Angulo Gonzalez David bought $27,400 worth of shares (20,000 units at $1.37), increasing direct ownership by 4% to 507,871 units (SEC Form 4)

      4 - SCYNEXIS INC (0001178253) (Issuer)

      9/16/24 8:00:27 AM ET
      $SCYX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SCYX
    SEC Filings

    See more
    • SEC Form 10-Q filed by SCYNEXIS Inc.

      10-Q - SCYNEXIS INC (0001178253) (Filer)

      5/15/25 4:01:36 PM ET
      $SCYX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by SCYNEXIS Inc.

      DEFA14A - SCYNEXIS INC (0001178253) (Filer)

      4/30/25 4:03:33 PM ET
      $SCYX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by SCYNEXIS Inc.

      DEF 14A - SCYNEXIS INC (0001178253) (Filer)

      4/30/25 4:01:58 PM ET
      $SCYX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SCYX
    Leadership Updates

    Live Leadership Updates

    See more
    • AUROBAC THERAPEUTICS welcomes two new independent members to its Board: Manos Perros, as Chairman, and Marco Taglietti

      Lyon - France, July 24, 2023 (GLOBE NEWSWIRE) -- AUROBAC THERAPEUTICS WELCOMES TWO NEW INDEPENDENT MEMBERS TO ITS BOARD: MANOS PERROS, AS CHAIRMAN, AND MARCO TAGLIETTI Dr Manos Perros and Dr Marco Taglietti are appointed new Independent Members of the Board of AUROBAC THERAPEUTICSDr Perros becomes Chairman of the Board These new appointments bring extensive US and international experience in company leadership and development of anti-infectives from R&D to commercialization Lyon (France), Thursday July 24, 2023 AUROBAC THERAPEUTICS SAS, a biopharmaceutical company developing the next generation of products to fight antimicrobial resistance (AMR), is delighted to announce th

      7/24/23 8:00:00 AM ET
      $SCYX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SCYNEXIS Reports First Quarter 2021 Financial Results and Provides Corporate Update

      Secured non-dilutive funding of approximately $35 million thus far in 2021, including licensing payments from Hansoh Pharma, the first tranche from a term loan agreement with Hercules and Silicon Valley Bank, and the monetization of the 2020 New Jersey NOLsAppointed Christine Coyne as Chief Commercial Officer to lead the launch of ibrexafungerp (Brexafemme®) for the treatment of vaginal yeast infections, following expected approval by June 1st Began dosing patients in a Phase 1 trial of the IV formulation of ibrexafungerpFurther strengthened balance sheet and projected cash runway into 2023 JERSEY CITY, N.J., May 17, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology c

      5/17/21 8:30:00 AM ET
      $SCYX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SCYNEXIS Appoints Accomplished Commercial Executive Christine Coyne as Chief Commercial Officer to Lead the Brexafemme® Launch

      Strengthening the management team with deep anti-infective commercial expertise across hospital and community settings ahead of anticipated approval of Brexafemme (ibrexafungerp) in June 2021 and H2:2021 launch JERSEY CITY, N.J., May 11, 2021 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the appointment of Christine Coyne as Chief Commercial Officer, effective May 10, 2021. Ms. Coyne will play a significant role in the anticipated U.S. launch and commercialization of Brexafemme, the expected trade name for ibrexafungerp, an oral antifungal p

      5/11/21 8:30:00 AM ET
      $SCYX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SCYX
    Financials

    Live finance-specific insights

    See more
    • GSK and SCYNEXIS Announce an Exclusive Agreement to Commercialise and Further Develop Brexafemme (ibrexafungerp), a Novel, First-in-Class Medicine to Treat Fungal Infection

      Brexafemme complements GSK's industry-leading infectious disease portfolio with an FDA approved treatment for vulvovaginal candidiasisSCYNEXIS will receive an upfront payment of $90 million with future performance-based milestone payments and tiered royaltiesSCYNEXIS retains rights to all other assets derived from enfumafungin, with GSK having a right of first negotiation to these pre-clinical and discovery stage assetsSCYNEXIS to host an investor call and webcast at 8:30 a.m. EDT today LONDON and JERSEY CITY, N.J., March 30, 2023 (GLOBE NEWSWIRE) -- GSK plc (NYSE:GSK) and SCYNEXIS, Inc. (NASDAQ:SCYX), today announced they have entered into an exclusive licence agreement for Brexafemme (i

      3/30/23 7:05:00 AM ET
      $GSK
      $SCYX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SCYNEXIS Reports Third Quarter 2022 Financial Results and Provides Corporate Update

      SCYNEXIS recently announced new strategic direction to refocus its resources on the clinical development of ibrexafungerp for severe, hospital-based indications.Ivor Macleod, a 30-year biopharma veteran, joined SCYNEXIS as Chief Financial Officer.Marco Taglietti, M.D., to retire as President and Chief Executive Officer of SCYNEXIS and step down from the Board of Directors on December 31, 2022. David Angulo, M.D., Chief Medical Officer of SCYNEXIS will become President and Chief Executive Officer and join the Board effective January 1, 2023.BREXAFEMME® (ibrexafungerp tablets) prescriptions continued to grow in Q3 2022, increasing 13% over Q2 2022, generating net revenues of $1.6 million in Q3

      11/9/22 7:00:00 AM ET
      $SCYX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SCYNEXIS to Report Third Quarter 2022 Financial Results and Provide a Corporate Update on November 9

      JERSEY CITY, N.J., Nov. 01, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced it will host a conference call and live webcast at 8:30 a.m. EDT on Wednesday, November 9, 2022, to provide a corporate update and discuss the Company's financial results for the third quarter ended September 30, 2022. Conference call and webcast details: Investors (domestic): (844) 826-3033Investors (international): (412) 317-5185Webcast:  LinkConference ID: 10172836 A live audio webcast can be accessed by visiting the Investor Relations section of the Company'

      11/1/22 8:30:00 AM ET
      $SCYX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SCYX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by SCYNEXIS Inc.

      SC 13G/A - SCYNEXIS INC (0001178253) (Subject)

      11/14/24 7:07:26 PM ET
      $SCYX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by SCYNEXIS Inc.

      SC 13G/A - SCYNEXIS INC (0001178253) (Subject)

      11/6/24 8:56:32 AM ET
      $SCYX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by SCYNEXIS Inc.

      SC 13G/A - SCYNEXIS INC (0001178253) (Subject)

      10/7/24 1:38:20 PM ET
      $SCYX
      Biotechnology: Pharmaceutical Preparations
      Health Care